Literature DB >> 7489357

Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.

T Alon1, I Hemo, A Itin, J Pe'er, J Stone, E Keshet.   

Abstract

Retinopathy of prematurity (ROP) is initiated by hyperoxia-induced obliteration of newly formed blood vessels in the retina of the premature newborn. We propose that vessel regression is a consequence of hyperoxia-induced withdrawal of a critical vascular survival factor. We show that regression of retinal capillaries in neonatal rats exposed to high oxygen, is preceded by a shut-off of vascular endothelial growth factor (VEGF) production by nearby neuroglial cells. Vessel regression occurs via selective apoptosis of endothelial cells. Intraocular injection of VEGF at the onset of experimental hyperoxia prevents apoptotic death of endothelial cells and rescues the retinal vasculature. These findings provide evidence for a specific angiogenic factor acting as a vascular survival factor in vivo. The system also provides a paradigm for vascular remodelling as an adaptive response to an increase in oxygen tension and suggests a novel approach to prevention of ROP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489357     DOI: 10.1038/nm1095-1024

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  375 in total

Review 1.  Glucose, VEGF-A, and diabetic complications.

Authors:  L E Benjamin
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  More weapons in the arsenal against ischemic retinopathy.

Authors:  E Keshet
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

3.  Severe retinopathy of prematurity and its association with different rates of survival in infants of less than 1251 g birth weight.

Authors:  J Vyas; D Field; E S Draper; G Woodruff; A R Fielder; J Thompson; N J Shaw; D Clark; R Gregson; J Burke; G Durbin
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-03       Impact factor: 5.747

4.  Control of apoptosis during angiogenesis by survivin expression in endothelial cells.

Authors:  D S O'Connor; J S Schechner; C Adida; M Mesri; A L Rothermel; F Li; A K Nath; J S Pober; D C Altieri
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  A fragment of human TrpRS as a potent antagonist of ocular angiogenesis.

Authors:  Atsushi Otani; Bonnie M Slike; Michael I Dorrell; John Hood; Karen Kinder; Karla L Ewalt; David Cheresh; Paul Schimmel; Martin Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

6.  Anti-angiogenic therapy for uveal melanoma--more haste, less speed.

Authors:  A W Stitt; T A Gardiner
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

Review 7.  Retinopathy of prematurity: recent advances in our understanding.

Authors:  C M Wheatley; J L Dickinson; D A Mackey; J E Craig; M M Sale
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

8.  Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?

Authors:  N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

9.  Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation.

Authors:  C Cursiefen; C Hofmann-Rummelt; M Küchle; U Schlötzer-Schrehardt
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

Review 10.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.